(2Z,5E)-3-ethyl-2-[[1-[(3-fluoro-4-methylphenyl)methyl]pyridin-1-ium-2-yl]methylidene]-5-[3-methyl-7-(trifluoromethyl)-1,3-benzothiazol-2-ylidene]-1,3-thiazolidin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: (2Z,5E)-3-ethyl-2-[[1-[(3-fluoro-4-methylphenyl)methyl]pyridin-1-ium-2-yl]methylidene]-5-[3-methyl-7-(trifluoromethyl)-1,3-benzothiazol-2-ylidene]-1,3-thiazolidin-4-one
• 化学式: C28H24F4N3OS2+
• 分子量: 558.6
• InChiKey: MTOIAUALYNBLPM-IMVLJIQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  38
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• US20140275169A1
  申请人：——

  公开号：US20140275169A1

  公开（公告）日：2014-09-18
• PHARMACEUTICAL COMPOUNDS AND USE OF SAME IN CANCER AND TAUOPATHIES
  申请人：REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20160000770A1

  公开（公告）日：2016-01-07

  Disclosed are compounds of formula (1)-(V): where the substituents are as provided herein. Further disclosed are methods of inhibiting tau aggregation, treating or ameliorating a tauopathy or cancer by administration of such a compound. Tau is a microtubule-binding protein that accumulates in a number of neurodegenerative disorders, including frontotemporal dementia and Alzheimer's disease (AD). The presence of abnormal tau correlates with neuron loss and memory deficits in patients with AD and other neurodegenerative disorders that involve tau accumulation.
• US9642843B2
  申请人：——

  公开号：US9642843B2

  公开（公告）日：2017-05-09
• US9808448B2
  申请人：——

  公开号：US9808448B2

  公开（公告）日：2017-11-07